Heterogeneity of Clazosentan Benefit after Aneurysmal Subarachnoid Hemorrhage Demonstrated in an Externally Validated Causal Policy Tree.
Le 01 Juil 2026
Auteur : Nishida K, Chrétien B, Muraoka S, Izumi T, Nishihori M, Goto S, Takeuchi I, Tashiro R, Sakata H, Vivien D, Mizuno M, Endo H, Saito R
Année : 2026
Journal : Neurocrit Care 1556-0961
PubMed Id : 42310190
Clazosentan reduces angiographic vasospasm after aneurysmal subarachnoid hemorrhage (aSAH), but functional benefit may vary across patients. We used causal machine learning to explore heterogeneity and derive an interpretable rule.
